



COPY OF PAPERS  
ORIGINALLY FILED

PATENT APPLICATION  
File No: 00-22

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of : Cindy A. Sprecher, Julia E. Novak, James W. West, Scott R.  
Presnell, Richard D. Holly, Andrew J. Nelson  
Serial No. : 09/825,561  
Group Art Unit : 1646  
Examiner : Li, Ruixiang  
Filed : April 3, 2001  
For : SOLUBLE ZALPHA11 CYTOKINE RECEPTORS  
Date Submitted : June 10, 2002

RECEIVED

JUN 20 2002

AMENDMENT FEE TRANSMITTAL

TECH CENTER 1600/2900

BOX NON-FEE AMENDMENT

Commissioner for Patents  
Washington, DC 20231

Sir:

Transmitted herewith is an Amendment for the above-mentioned application.  
The fee required to be filed with the accompanying amendment has been calculated as shown below:

CLAIMS AS AMENDED

	Claims Remaining After Amendment	Highest No. Covered by Previous Payments	Present Extra	Extra Rate	Fee
Total	11	-47		\$9.00	\$000.00
Independent	3	-13		\$42.00	\$000.00
1st Presentation of Multiple Dependent Claim				\$140.00	\$000.00
Total					\$000.00

Applicants claim small entity status. Please charge any required fee to  
ZymoGenetics, Inc., Deposit Account No. 26-0290. A duplicate of this sheet is enclosed.

Respectfully submitted,

Jennifer K. Johnson, J.D.  
Registration No. 43,696



COPY OF PAPERS  
ORIGINALLY FILED

PATENT APPLICATION

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231.

6/10/02  
Date

Marianne Carello  
Marianne Carello

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Sprecher, Cindy A., Novak, Julia E., West, James W., Presnell,  
Scott R., Holly, Richard D., and Nelson, Andrew J.  
Application No. : 09/825,561  
Filed : April 3, 2001  
For : SOLUBLE ZALPHA11 CYTOKINE RECEPTORS

Examiner : Ruixiang Li  
Art Unit : 1646  
Docket No.: 00-22  
Date : June 10, 2002

RECEIVED

JUN 20 2002

TECH CENTER 1600/2900

Box Non-Fee Amendment  
Commissioner for Patents  
Washington, D.C. 20231

RESPONSE TO OFFICE ACTION

Sir: